PubMed | Asan Medical Center Seoul
Type: Journal Article | Journal: Anaesthesia and intensive care | Year: 2011
A prospective cohort study was performed to determine the optimal dose of vancomycin to maintain a serum trough concentration of at least 15 to 20 mg/l and to assess the efficacy of this target vancomycin concentration in the treatment of methicillin-resistant Staphylococcus aureus pneumonia. Vancomycin pharmacokinetic parameters were estimated using a CAPSIL software program from serum concentrations of 141 patients with pneumonia treated with vancomycin, regardless of methicillin-resistant Staphylococcus aureus status, at a 28-bed medical intensive care unit. Vancomycin trough concentrations and other pharmacokinetic parameters were compared between five groups of patients differing in their renal function: (1) creatinine clearance > or =60 ml/minute, (2) creatinine clearance 30 to 60 ml/minute, (3) creatinine clearance <30 ml/minute, (4) on intermittent haemodialysis, and (5) on continuous renal replacement therapy. More than 70% of patients failed to reach the recommended therapeutic serum trough concentrations: a higher dose of vancomycin is necessary to maintain serum trough concentration at 15 to 20 mg/l, particularly in critically ill patients with creatinine clearance above 60 ml/minute and in those on intermittent haemodialysis. Among patients with methicillin-resistant Staphylococcus aureus pneumonia, no significant differences were observed in the treatment success rate, length of intensive care unit stay, and intensive care unit mortality rate between patients with vancomycin trough concentrations of >20 mg/l, 15 to 20 mg/l and <15 mg/l.
PubMed | Asan Medical Center Seoul and Seoul National University
Type: Comparative Study | Journal: International journal of clinical and experimental pathology | Year: 2015
To evaluate the status of peritumoral pseudocapsules in renal tumors and the effects of clinicopathological factors on their formation.From January 2011 to December 2012, 258 patients with solitary clinical stage T1a renal tumors who underwent partial nephrectomy were analyzed. Status of pseudocapsule was re-evaluated by a pathologist.The mean long diameter ( SD) of the tumor and the width of the safety margin were 2.17 ( 0.94) cm and 3.2 ( 2.4) mm, respectively. A complete pseudocapsule was identified in 152 (58.9%) tumors, an incomplete pseudocapsule was identified in 69 (26.7%) tumors, and no pseudocapsule was identified in 37 (14.3%) tumors. Out of 152 tumors with complete pseudocapsules, 45 (29.6%) were confirmed to directly invade the renal parenchyma. In a multivariable analysis, age (odds ratio [OR], 1.045; 95% confidence interval [CI], 1.021-1.070, P < 0.001) and histologic subtype (chromophobe type: OR, 19.455; 95% CI, 4.233-89.471, P < 0.001; oncocytoma: OR, 11.307; 95% CI, 1.357-94.198, P = 0.025) were significant factors for an incomplete or absent pseudocapsule.Peritumoral pseudocapsules are absent or incomplete in a significant portion of renal tumors. Old age as well as chromophobe and oncocytoma histologic subtypes were significant risk factors for an incomplete or absent peritumoral pseudocapsule.